May 9, 2024 11:23 AM EDT
R&D

Rapt Ther­a­peu­tics winds down Phase 2 stud­ies of lead can­di­date in wake of clin­i­cal holds

Ayisha Sharma

News Reporter

Rapt Ther­a­peu­tics said it will close and un­blind two mid-stage tri­als in atopic der­mati­tis and asth­ma af­ter they were put on clin­i­cal hold ear­li­er this …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times